Miglustat

Miglustat
Klinički podaci
Prodajno ime	Miglustat, Hydrochloride, Zavesca
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	6 do 7 sati
Identifikatori
CAS broj	72599-27-0
ATC kod	A16AX06 (WHO)
PubChem	CID 51634
DrugBank	DB00419
ChemSpider	46764
ChEBI	CHEBI:50381
ChEMBL	CHEMBL1029
Hemijski podaci
Formula	C10H21NO4
Molarna masa	219,278
	SMILES CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO; ;
	InChI InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 ; Key:UQRORFVVSGFNRO-UTINFBMNSA-N ;
Fizički podaci
Tačka topljenja	169—172 °C (336—342 °F)

Miglustat je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 219,278 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	5
Broj donora vodonika	4
Broj rotacionih veza	4
Particioni koeficijent^[9] (ALogP)	-0,6
Rastvorljivost^[10] (logS, log(mol/L))	-0,1
Polarna površina^[11] (PSA, Å²)	84,2

Reference

^ van Giersbergen PL, Dingemanse J. (октобар 2007). „Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase”. J Clin Pharmacol. 47 (10): 1277—82. PMID 17720777. doi:10.1177/0091270007305298. . Epub 2007 Aug 24.
^ Weinreb, N. J.; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P. (новембар 2005). „Guidance on the use of miglustat for treating patients with type 1 Gaucher disease”. Am J Hematol. 80 (3): 223—9. PMID 16247743. doi:10.1002/ajh.20504. .
^ Patterson, M. C.; Vecchio D; Prady H; Abel L; Wraith JE. (септембар 2007). „Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study”. Lancet Neurol. 6 (9): 765—72. PMID 17689147. doi:10.1016/S1474-4422(07)70194-1. .
^ Moyses, C. (мај 2003). „Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease”. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 358 (1433): 955—60. PMC 1693174 . PMID 12803929. doi:10.1098/rstb.2003.1271.
^ Wraith, J. E.; Imrie J. (2009). „New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat”. Ther Clin Risk Manag. 2009 (5): 877—87. PMC 2781062 . PMID 19956552. doi:10.2147/tcrm.s5777 . . Epub 2009 Nov 18.
^ McCormack, P. L.; Goa KL. (2003). „Miglustat”. Drugs. 63 (22): 2427—34. PMID 14609352. doi:10.2165/00003495-200363220-00006. ; discussion 2435-6.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Miglustat

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] van Giersbergen PL, Dingemanse J. (октобар 2007). „Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase”. J Clin Pharmacol. 47 (10): 1277—82. PMID 17720777. doi:10.1177/0091270007305298. . Epub 2007 Aug 24.

[2] Weinreb, N. J.; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P. (новембар 2005). „Guidance on the use of miglustat for treating patients with type 1 Gaucher disease”. Am J Hematol. 80 (3): 223—9. PMID 16247743. doi:10.1002/ajh.20504. .

[3] Patterson, M. C.; Vecchio D; Prady H; Abel L; Wraith JE. (септембар 2007). „Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study”. Lancet Neurol. 6 (9): 765—72. PMID 17689147. doi:10.1016/S1474-4422(07)70194-1. .

[4] Moyses, C. (мај 2003). „Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease”. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 358 (1433): 955—60. PMC 1693174 . PMID 12803929. doi:10.1098/rstb.2003.1271.

[5] Wraith, J. E.; Imrie J. (2009). „New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat”. Ther Clin Risk Manag. 2009 (5): 877—87. PMC 2781062 . PMID 19956552. doi:10.2147/tcrm.s5777 . . Epub 2009 Nov 18.

[6] McCormack, P. L.; Goa KL. (2003). „Miglustat”. Drugs. 63 (22): 2427—34. PMID 14609352. doi:10.2165/00003495-200363220-00006. ; discussion 2435-6.

[7] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[8] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[9] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[10] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[11] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]